Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 25 versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 25 versus UNIRETIC.
CAPOZIDE 50/25 vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category C
Category C
ACE Inhibitor/Diuretic Combination
ACE Inhibitor and Diuretic